-
Preclinical Screening of Compounds that Modulate the Pathological Interplay between Alpha-synuclein and Synapsin III for the Treatment of Parkinson’s Disease
… and restore dopamine release and motor abilities. Impact on Diagnosis/Treatment of Parkinson’s disease: The therapeutic … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Testing the Neuroprotective Effects of Modulating Atp6v0a1
… involve abnormal accumulation of alpha-synuclein. Impact on Diagnosis/Treatment of Parkinson’s disease: If repression … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Use of Itaconate to Improve Metabolic Regulation in Parkinson's Disease
… buffering inflammation and modulating metabolism. Impact on Diagnosis/Treatment of Parkinson’s disease: If successful, … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease
… and brain injury compared to placebo. Impact on Diagnosis/Treatment of Parkinson’s disease: The project has … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Using AZP2006 (Ezeprogind) to Stabilize Progranulin – A Novel Therapeutic Strategy for GBA1-linked Parkinson’s Disease
… GBA, which will enforce the lysosomal phenotype. Impact on Diagnosis/Treatment of Parkinson’s disease: AZP2006 in … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Therapeutic Efficacy of IC 100 in Small Models
… brain may contribute to PD, however, this has not been clearly defined. Recent data have shown that activation of … brain inflammation improves disease outcomes. Impact on Diagnosis/Treatment of Parkinson’s disease: This study will … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …